Amphista Therapeutics

Amphista Therapeutics developed therapies using targeted protein degradation for severe diseases including cancer. 

White arrow on a road pointing to the rising sun
Research

Amphista's targeted glue sticks the landing in early AML test

Amphista has reported preclinical leukemia data on its protein degrader, positioning the biotech to target a 2026 start date for a phase 1 trial.
Nick Paul Taylor Dec 8, 2025 7:40am
Charming view of the seaside resort town of Kas in Turkey Romantic lighthouse at the entrance to the port and a paraglider f

BMS vet answers Foghorn’s call for CBO—Chutes & Ladders

Sep 6, 2024 8:30am
illustration of protein degradation

Amphista protein degraders effective against cancer in animals

Jan 24, 2024 4:30am
parachute south africa cape town

Cerevel swaps CEO—Chutes & Ladders

May 5, 2023 9:30am
photo of the exterior of EMD Serono

Merck KGaA shrinks US R&D team as layoffs batter industry

Jan 23, 2023 10:00am
Fierce Biotech Fierce 15 logo

Fierce Biotech's 2022 Fierce 15

Sep 12, 2022 3:00am